RxDoctor Payments Data

Gregory White, MD

Pulmonary Disease · Texarkana, TXNPI 1649406752

Payments from drug & device makers

$12,835in general payments, 2019–2025

Across 220 payments — averaging $58.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$8K
  • AstraZeneca$989
  • GSK$587
  • United Therapeutics Corporation$585
  • Insmed, Inc.$504
  • Actelion Pharmaceuticals US, Inc.$433
  • plus $2K from 28 others

What the payments were for

  • Consulting fees$5,62544%
  • Travel & lodging$1,25610%
  • Food & beverage$5,49743%
  • Education$4584%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,835 in reported general payments places this provider in the 75th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$259,853
Medicare patients
742
Services billed
4,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ambrisentan25$45,664
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$29,577
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$11,761
EliquisApixaban11$6,260
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$3,060
Albuterol Sulfate HfaAlbuterol Sulfate21$590
Azithromycin41$331
Pantoprazole Sodium42$325
Levofloxacin66$321
Montelukast Sodium49$299
Prednisone135$240
Losartan Potassium30$214
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$186
Esomeprazole Magnesium12$167
Furosemide15$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$587$29,57740 claims
AstraZenecaBreztri Aerosphere$989$11,76119 claims
Boehringer IngelheimStiolto Respimat$127$3,06011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Texarkana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →